PDL BioPharma — Q2 2020 Earnings Presentation
17 slides from PDL BioPharma's earnings presentation, Aug 6, 2020
Slide 1: Second Quarter 2020 Financial Results Conference Call
PDL Second Quarter 2020 Financial Results Conference Calll August 6, 2020 Nasdaq: PDLI
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forwardooking statements inducing POL's expectations with respect to revenues, expenses, net income and cash provided by operating aciiviies. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ mat
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It ‘The Company has filed a definitive proxy statement (the “2020 Proxy Statement’) with the SEC in connection with the solicitation of proxies for the 2020 Annual Meeting. STOCKHOLDERS ARE URGED TO READ THE 2020 PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR S
Slide 4: Significant Progress in Asset Monetization
Significant Progress in Asset Monetization o PDL has made significant progress in the execution of our asset monetization strategy o We remain committed to our strategy aimed at monetizing our assets and at distributing their value in the most tax efficient manner to our stockholders o We are reques
Slide 5: Timely Distribution of Evofem Stock
Timely Distribution of Evofem Stock o We distributed all 13.3 million EVFM common shares held by PDL througha pro rata, special, one-time dividend o Distribution was timed to be shortly before the Phexxi™ FDA PDUFA date o Phexxi™ was FDA-approved on May 22, 2020, leading to a significant increase in
Slide 6: Noden: Divest for Up to $48.25 Million
Noden: Divest for Up to $48.25 Million o We announced our entry into a definitive agreement to sell 100% of the stock in Noden to private equity firm Stanley Capital o The total value of this cash transaction is up to $48.25 million = We will receive a payment of approximately $12 million when the t
Slide 7: LENSAR: Well-positioned for Spinoff
LENSAR: Well-positioned for Spinoff o On July 17, we announced a confidential filing of a Form 10 registration statement for a potential spinoff as a publicly traded company o PDL continues to evaluate its strategic options for LENSAR and cannot provide assurance that it will proceed with a spinoff
Slide 8: Strengthening Innovation Lead with ALLY
Strengthening Innovation Lead with ALLY™ o Streamline IV system enables surgeons to optimize their surgical management of astigmatism = Between 70-90% of cataract patients have treatable, visually significant astigmatism prior to surgery, but this astigmatism remains largely uncorrected post-surgery
Slide 9: Royalty Portfolio
Royalty Portfolio Glumetza V indefinite ( Aaya — 3ykPevomed — Ee mencs, —_§/9018 weneeccieXB 3k Devomea (mane Ll, 5/2026 $260.5M -$472.3M coumemeetenn yanssen Jr 9/2023) 2OERAallan BE Dvoms OEE oy, 12/2026) | J il, eee es Ea sanoricenzyme yy 4/2022 $65.6M $22.9M ZALVISO’ AcelRx 2030 $65.0M $0.9M SiM
Slide 10: Cost Efficiencies to Maximize Returns
10 Cost Efficiencies to Maximize Returns o The assets held by PDL and accounting for the transactions completed to date, we estimate in the Proxy Statement the value of PDL, includingthe distribution of EVFM common shares, to be in the range of $360 million to $680 million = Implies a per share valu
Slide 11: Dissolution Plan for Efficient Wind Down
"1 Dissolution Plan for Efficient Wind Down o Virtual 2020 Annual Meeting of Stockholders is scheduled for August 19, 2020 o Our Board urges a vote “FOR’ the first five proposals on the Proxy Statement o Proposal #3 seeks stockholder approval for the dissolution of the company pursuantto the Plan of
Slide 12: Key Points in Plan of Dissolution
Key Points in Plan of Dissolution o The company will exist after filing the Certificate of Dissolution for at least 3 years, solely for wind-down purposes as required under the laws of Delaware o Time allows for managing potential litigation, resolving any claims and disputes, monetizing any remaini
Slide 13: Other Financial Considerations
Other Financial Considerations o The CARES Act permits taxpayers to carry net operating losses back 5 years « Transactions in 2020 may result in the recognition of ordinary tax losses that could be applied to prior tax years in which PDL was a substantial tax payor = There can be no assurance that s
Slide 14: Second Quarter 2020 Financials (unaudited)
Second Quarter 2020 Financials (unaudited) ‘Three Months Ended Six Months Ended June 20, June 20, tn thousands, exceet per share an cunt 2020 2019 2020 2019 Product revenue, net S 4009 § 5268. ais $10,004 Lease revenue 359 1,308 1,836 2532 Senice revenue 590. 385, 71582 1612 Royalties from Queen et
Slide 15: Second Quarter 2020 Financials (unaudited)
15 Second Quarter 2020 Financials (unaudited) GAAP to Non-GAAP Net (Loss) Income Reconciliation (in thousands) ‘Three Months Ended Six Months Ended June3o, June 30, Se = a GAAP net (loss) income attributed to PDL’s shareholders, as reported $ (49971) $ (4419) _$ (81.694) $ 2.261 Adjustments: Mark-to
Slide 16: Second Quarter 2020 Financials (unaudited)
16 Second Quarter 2020 Financials (unaudited) Consolidated balance sheet data (in thousands) Cash and cash equivalents Notes receivable Assets held for sale Total assets Liabilities held for sale Convertible notes payable Total stockholders' equity June 30, December 31, 2020 2019 $ 105,446 $ 168,982
Slide 17: Questions & Answers
PDL Questions & Answers